サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552644

糖尿病向け非インスリン療法の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

Non-insulin Therapies for Diabetes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 142 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
糖尿病向け非インスリン療法の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年
出版日: 2024年07月11日
発行: Transparency Market Research
ページ情報: 英文 142 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病向け非インスリン療法市場- 調査範囲

TMRの調査レポート「糖尿病向け非インスリン療法の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の糖尿病向け非インスリン療法市場の収益と予測を提供しています。また、2024年から2034年までの世界の糖尿病向け非インスリン療法市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、糖尿病向け非インスリン療法市場を推察しました。

市場スナップショット
2023年の市場規模 318億米ドル
2034年の市場規模 586億米ドル
CAGR 5.8%

当レポートでは、世界の糖尿病向け非インスリン療法市場の競合情勢について調査しています。世界の糖尿病向け非インスリン療法市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の糖尿病向け非インスリン療法市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：薬剤クラス別、2020-2034年
    • ビグアナイド
    • スルホニル尿素
    • チアゾリジンジオン
    • アルファグルコシダーゼ阻害剤
    • DPP-4阻害剤
    • GLP-1アナログ
    • ナトリウム-グルコース共輸送体-2（SGLT2）阻害剤
  • 市場の魅力分析：薬剤クラス別

第7章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：投与経路別、2020-2034年
    • 経口
    • 筋肉内
  • 市場の魅力分析：投与経路別

第8章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2020-2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力分析：流通チャネル別

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋地域の市場分析と予測

第13章 ラテンアメリカの市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

  • 市場企業- 競争マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023）
  • 企業プロファイル
    • GSK plc
    • Eli Lilly and Company
    • Sumitomo Pharma
    • Intarcia Therapeutics
    • Servier Laboratories
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Dong-A Pharmaceutical Co., Ltd.
    • Luye Pharma Group
    • Eurofarma Laboratories SA
図表

List of Tables

  • Table 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 03: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 07: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 08: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 11: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 12: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 16: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 19: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 23: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 24: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Non-insulin Therapies for Diabetes Market Value Share, by Drug Class, 2023
  • Figure 04: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 05: Global Non-insulin Therapies for Diabetes Market Value Share, by Route of Administration, 2023
  • Figure 06: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 07: Global Non-insulin Therapies for Diabetes Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Non-insulin Therapies for Diabetes Market Value Share, by Region, 2023
  • Figure 09: Global Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 11: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 13: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 14: Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 22: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 23: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 26:North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 31: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 32: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 35: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 40: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 41: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 44: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 49: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 53: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 58: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 59: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 62: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL86328

Non-insulin Therapies for Diabetes Market - Scope of Report

TMR's report on the global non-insulin therapies for diabetes market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-insulin therapies for diabetes market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-insulin therapies for diabetes market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-insulin therapies for diabetes market.

Market Snapshot
Market Value in 2023US$ 31.8 Bn
Market Value in 2034US$ 58.6 Bn
CAGR5.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-insulin therapies for diabetes market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-insulin therapies for diabetes market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-insulin therapies for diabetes market.

The report delves into the competitive landscape of the global non-insulin therapies for diabetes market. Key players operating in the global non-insulin therapies for diabetes market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-insulin therapies for diabetes market profiled in this report.

Key Questions Answered in Global non-insulin therapies for diabetes Market Report:

  • What is the sales/revenue generated by non-insulin therapies for diabetes across all regions during the forecast period?
  • What are the opportunities in the global non-insulin therapies for diabetes market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Non-insulin Therapies for Diabetes Market - Research Objectives and Research Approach

The comprehensive report on the global non-insulin therapies for diabetes market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-insulin therapies for diabetes market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-insulin therapies for diabetes market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Non-insulin Therapies for Diabetes Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Non-insulin Therapies for Diabetes Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Biguanides
    • 6.3.2. Sulfonylureas
    • 6.3.3. Thiazolidinediones
    • 6.3.4. Alpha-Glucosidase Inhibitors
    • 6.3.5. DPP-4 Inhibitors
    • 6.3.6. GLP-1 Analogs
    • 6.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 7.3.1. Oral
    • 7.3.2. Intramuscular
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034
    • 10.3.1. Biguanides
    • 10.3.2. Sulfonylureas
    • 10.3.3. Thiazolidinediones
    • 10.3.4. Alpha-Glucosidase Inhibitors
    • 10.3.5. DPP-4 Inhibitors
    • 10.3.6. GLP-1 Analogs
    • 10.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 10.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 10.4.1. Oral
    • 10.4.2. Intramuscular
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacy
    • 10.5.2. Retail Pharmacy
    • 10.5.3. Online Pharmacy
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Class
    • 10.7.2. By Route of Administration
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. Biguanides
    • 11.3.2. Sulfonylureas
    • 11.3.3. Thiazolidinediones
    • 11.3.4. Alpha-Glucosidase Inhibitors
    • 11.3.5. DPP-4 Inhibitors
    • 11.3.6. GLP-1 Analogs
    • 11.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 11.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.4.1. Oral
    • 11.4.2. Intramuscular
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacy
    • 11.5.2. Retail Pharmacy
    • 11.5.3. Online Pharmacy
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034
    • 12.3.1. Biguanides
    • 12.3.2. Sulfonylureas
    • 12.3.3. Thiazolidinediones
    • 12.3.4. Alpha-Glucosidase Inhibitors
    • 12.3.5. DPP-4 Inhibitors
    • 12.3.6. GLP-1 Analogs
    • 12.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 12.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.4.1. Oral
    • 12.4.2. Intramuscular
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacy
    • 12.5.2. Retail Pharmacy
    • 12.5.3. Online Pharmacy
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Route of Administration
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. Biguanides
    • 13.3.2. Sulfonylureas
    • 13.3.3. Thiazolidinediones
    • 13.3.4. Alpha-Glucosidase Inhibitors
    • 13.3.5. DPP-4 Inhibitors
    • 13.3.6. GLP-1 Analogs
    • 13.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 13.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.4.1. Oral
    • 13.4.2. Intramuscular
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospital Pharmacy
    • 13.5.2. Retail Pharmacy
    • 13.5.3. Online Pharmacy
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Route of Administration
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Non-insulin Therapies for Diabetes Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Class, 2020-2034
    • 14.3.1. Biguanides
    • 14.3.2. Sulfonylureas
    • 14.3.3. Thiazolidinediones
    • 14.3.4. Alpha-Glucosidase Inhibitors
    • 14.3.5. DPP-4 Inhibitors
    • 14.3.6. GLP-1 Analogs
    • 14.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
  • 14.4. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.4.1. Oral
    • 14.4.2. Intramuscular
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacy
    • 14.5.2. Retail Pharmacy
    • 14.5.3. Online Pharmacy
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Route of Administration
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. GSK plc
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Eli Lilly and Company
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Sumitomo Pharma
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Intarcia Therapeutics
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Servier Laboratories
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Pfizer Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Merck & Co., Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Dong-A Pharmaceutical Co., Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Luye Pharma Group
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Eurofarma Laboratories SA
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview